Cardiology

Your Article Summary

See Latest Articles

New Anticoagulants for Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 09/15/09

Sobieraj–Teague M et al. – Atrial fibrillation is already the most common clinically significant cardiac arrhythmia and a common cause of stroke. Vitamin K antagonists are very effective for the prevention of cardioembolic stroke but have numerous limitations that limit their uptake in eligible patients with AF and reduce their effectiveness in treated patients. A new vitamin K antagonist (ATI–5923) with improved pharmacological properties compared with warfarin is also being evaluated in a phase III trial. None of the new agents have as yet been approved for clinical use.

Today in Arrhythmias/EP...keeping you current

Receive free subspecialty "5-minute updates" via email

Acute Coronary Syndromes: Diagnosis and Management, Part I
Mayo Clinic Proceedings, 10/05/09

New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09

Acute medical management of the non-ST-segment elevation acute coronary syndromes (NSTE-ACS) in older patients
Archives of Gerontology and Geriatrics, 10/14/09

See All of Arrhythmias/EP

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09

Effectiveness of Two-Year Clopidogrel + Aspirin in Abolishing the Risk of Very Late Thrombosis After Drug-Eluting Stent Implantation (from the TYCOON [Two-Year ClOpidOgrel Need] Study)
The American Journal of Cardiology, 11/05/09

Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia
Annals of Internal Medicine, 11/03/09

See All of Clinical Pharmacology